Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond.
作者信息
Keiffer Gina, Aderhold Kimberly L, Palmisiano Neil D
机构信息
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
出版信息
Front Oncol. 2020 Dec 22;10:562219. doi: 10.3389/fonc.2020.562219. eCollection 2020.
Abstract
摘要
相似文献
1
Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond.FLT3突变型急性髓系白血病的一线治疗：回顾RATIFY试验及其他。
Front Oncol. 2020 Dec 22;10:562219. doi: 10.3389/fonc.2020.562219. eCollection 2020.
2
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.在 FLT3 突变的急性髓系白血病的临床前模型中，Bcl-2 的抑制作用与米哚妥林和吉特替尼协同增强抗白血病活性。
Clin Cancer Res. 2019 Nov 15;25(22):6815-6826. doi: 10.1158/1078-0432.CCR-19-0832. Epub 2019 Jul 18.
3
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.吉瑞替尼：一种用于急性髓系白血病的新型FLT3抑制剂。
Biomark Res. 2019 Sep 11;7:19. doi: 10.1186/s40364-019-0170-2. eCollection 2019.
4
Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.将 FLT3 抑制剂纳入 FLT3 突变型急性髓系白血病的一线治疗。
Best Pract Res Clin Haematol. 2019 Jun;32(2):154-162. doi: 10.1016/j.beha.2019.05.006. Epub 2019 May 12.
5
Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.吉列替尼治疗的急性髓系白血病患者中的巨核细胞扩增与AXL抑制有关。
Front Oncol. 2020 Dec 9;10:585151. doi: 10.3389/fonc.2020.585151. eCollection 2020.
6
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.米哚妥林：一种用于FLT3突变的急性髓系白血病和系统性肥大细胞增多症患者的新型治疗药物。
Ther Adv Hematol. 2017 Sep;8(9):245-261. doi: 10.1177/2040620717721459. Epub 2017 Aug 19.
7
Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.quizartinib是一种选择性FLT3抑制剂，在RAS介导的米哚妥林耐药急性髓系白血病细胞的临床前模型中维持抗白血病活性。
Oncotarget. 2020 Mar 17;11(11):943-955. doi: 10.18632/oncotarget.27489.
8
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.米哚妥林联合标准化疗治疗新诊断的FMS样酪氨酸激酶3（FLT3）突变阳性急性髓系白血病。
Ann Pharmacother. 2018 Apr;52(4):364-369. doi: 10.1177/1060028017747900. Epub 2017 Dec 12.
9
Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.Fms样酪氨酸激酶3（FLT3）配体（FL）对FLT3抑制剂吉瑞替尼在过表达FL细胞异种移植小鼠中的抗肿瘤活性的影响。
Oncotarget. 2019 Oct 22;10(58):6111-6123. doi: 10.18632/oncotarget.27222.
10
[Pharmacological and clinical profile of gilteritinib (Xospata tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia].吉瑞替尼（Xospata片剂，40毫克）的药理及临床概况，一种用于复发或难治性FLT3突变急性髓系白血病的治疗药物
Nihon Yakurigaku Zasshi. 2021;156(1):37-46. doi: 10.1254/fpj.20050.
引用本文的文献
1
[Clinical study of induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of FLT3-ITD(+) acute myeloid leukemia with normal karyotype].[诱导化疗后行异基因造血干细胞移植治疗核型正常的FLT3-ITD(+)急性髓系白血病的临床研究]
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):230-235. doi: 10.3760/cma.j.issn.0253-2727.2023.03.009.
2
The clinical impact of the molecular landscape of acute myeloid leukemia.急性髓系白血病分子特征的临床影响。
Haematologica. 2023 Feb 1;108(2):308-320. doi: 10.3324/haematol.2022.280801.
3
Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies.鞘脂在血液系统恶性肿瘤中的多方面作用的研究进展。
Int J Mol Sci. 2022 Oct 22;23(21):12745. doi: 10.3390/ijms232112745.
4
In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge.探寻继发性急性髓系白血病的遗传预后因素及治疗方法——当前知识的叙述性综述
J Clin Med. 2022 Jul 23;11(15):4283. doi: 10.3390/jcm11154283.
本文引用的文献
1
Potential targeting of FLT3 acute myeloid leukemia.FLT3 急性髓系白血病的潜在靶点。
Haematologica. 2021 Mar 1;106(3):671-681. doi: 10.3324/haematol.2019.240754.
2
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.FLT3 抑制剂在急性髓系白血病中的应用：十个常见问题。
Leukemia. 2020 Mar;34(3):682-696. doi: 10.1038/s41375-019-0694-3. Epub 2020 Jan 9.
3
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
4
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.FLT3 抑制剂在急性髓系白血病中的临床应用考虑。
Crit Rev Oncol Hematol. 2019 Sep;141:125-138. doi: 10.1016/j.critrevonc.2019.06.011. Epub 2019 Jun 28.
5
Availability of FLT3 inhibitors: how do we use them?FLT3 抑制剂的可及性：我们如何使用它们？
Blood. 2019 Aug 29;134(9):741-745. doi: 10.1182/blood.2019876821. Epub 2019 Jun 26.
6
FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications.FMS 样酪氨酸激酶 3/FLT3：从基础科学到临床意义。
Physiol Rev. 2019 Jul 1;99(3):1433-1466. doi: 10.1152/physrev.00029.2018.
7
What FLT3 inhibitor holds the greatest promise?哪种FLT3抑制剂最具前景？
Best Pract Res Clin Haematol. 2018 Dec;31(4):401-404. doi: 10.1016/j.beha.2018.09.008. Epub 2018 Sep 20.
8
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.一项在新诊断为急性髓系白血病患者中进行的quizartinib 联合诱导和巩固化疗的 1 期研究。
Am J Hematol. 2018 Feb;93(2):213-221. doi: 10.1002/ajh.24974. Epub 2017 Dec 4.
9
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
10
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
Zotero 插件